Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Filipits

Showing results (51-60 of 122) with videos related to

Pageof 13
Sort By:
Molecular Imaging and Biology|January 18, 2019
PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [<sup>18</sup>F]FDG PET/CTHeinrich Magometschnigg, Katja Pinker, Thomas Helbich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2003
High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelinGudrun Pohl, Margaretha Rudas, Otto Dietze, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study GroupMartin Filipits, Gudrun Pohl, Margaretha Rudas, et al.
Anticancer Research|March 6, 2014
Low protein expression of MET in ER-positive and HER2-positive breast cancerFlora Zagouri, Anita Brandstetter, Dimitrios Moussiolis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2020
Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast CancerIvana Sestak, Martin Filipits, Richard Buus, et al.
Clinical Neuropathology|December 24, 2013
Clinical Neuropathology practice news 1-2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastomaMatthias Preusser, Anna S Berghoff, Claudia Manzl, et al.
Anticancer Research|October 28, 2020
Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma SamplesMartin Filipits, Matthias Preusser, Johannes A Hainfellner, et al.
Neuroendocrinology|March 2, 2012
Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathwayZsuzsanna Bago-Horvath, Wolfgang Sieghart, Michael Grusch, et al.
Oncotargets and Therapy|August 1, 2015
Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?Aris Giannos, Martin Filipits, Flora Zagouri, et al.
Lung Cancer (Amsterdam, Netherlands)|August 8, 2013
Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITAStephen L Graziano, Benjamin Lacas, Robin Vollmer, et al.
Pageof 13

Showing results (51-60 of 122) with videos related to

Sort By:
Pageof 13
Molecular Imaging and Biology|January 18, 2019
PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [<sup>18</sup>F]FDG PET/CTHeinrich Magometschnigg, Katja Pinker, Thomas Helbich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2003
High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelinGudrun Pohl, Margaretha Rudas, Otto Dietze, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study GroupMartin Filipits, Gudrun Pohl, Margaretha Rudas, et al.
Anticancer Research|March 6, 2014
Low protein expression of MET in ER-positive and HER2-positive breast cancerFlora Zagouri, Anita Brandstetter, Dimitrios Moussiolis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2020
Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast CancerIvana Sestak, Martin Filipits, Richard Buus, et al.
Clinical Neuropathology|December 24, 2013
Clinical Neuropathology practice news 1-2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastomaMatthias Preusser, Anna S Berghoff, Claudia Manzl, et al.
Anticancer Research|October 28, 2020
Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma SamplesMartin Filipits, Matthias Preusser, Johannes A Hainfellner, et al.
Neuroendocrinology|March 2, 2012
Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathwayZsuzsanna Bago-Horvath, Wolfgang Sieghart, Michael Grusch, et al.
Oncotargets and Therapy|August 1, 2015
Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?Aris Giannos, Martin Filipits, Flora Zagouri, et al.
Lung Cancer (Amsterdam, Netherlands)|August 8, 2013
Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITAStephen L Graziano, Benjamin Lacas, Robin Vollmer, et al.
Pageof 13